January 1, 2001Thrombosis and Haemostasis
Open Multicentre Study of the P 2T Receptor Antagonist AR-C69931MX Assessing Safety, Tolerability and Activity in Patients with Acute Coronary Syndromes
Why the study?
Is intravenous AR-C69931MX safe, tolerable, and active in inhibiting platelet aggregation in patients with acute coronary syndromes?
Population
n=39 patients with unstable angina or non-Q wave myocardial infarction, receiving aspirin and heparin…
Design
Cohort, open-label
Follow-up
30 days
Authors
Discussion
Loading...
Member takes
Implication
Supports early testing of potent ADP antagonism in ACS; leaves open outcome benefits versus standards in randomized trials.
Structured PICO
Is intravenous AR-C69931MX safe, tolerable, and active in inhibiting platelet aggregation in patients with acute coronary syndromes?
P
Population
n=39 patients with unstable angina or non-Q wave myocardial infarction, receiving aspirin and heparin, across 5 hospitals.
I
Intervention
Intravenous AR-C69931MX with stepped dose increments over 3 h to a plateau of 2 microg/kg/min for 21 h (n=12) or up to 69 h (n=13), or 4 microg/kg/min for up to 69 h (n=14).
O
Outcome
Safety parameters, platelet aggregation induced by ADP 3 micromol/L (impedance aggregometry), bleeding time, and plasma concentrations of AR-C69931XX.safety
Intravenous AR-C69931MX is a potent, short-acting platelet ADP receptor antagonist that is well tolerated and achieves near-complete platelet inhibition in ACS patients.
Cite This Study
Oldroyd et al. (2001) studied this question.